Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FOB value of exports Rs crores ・Standalone data |
|
|||||||||||
| Number of manufacturing units count ・Standalone data |
||||||||||||
| Number of permanent employees count ・Standalone data |
||||||||||||
| Number of products count ・Standalone data |
||||||||||||
| Top 5 customers concentration % ・Standalone data |
||||||||||||
| Installed capacity for capsules million units per month ・Standalone data |
||||||||||||
| Installed capacity for dry syrups MT per month ・Standalone data |
||||||||||||
| Installed capacity for tablets million units per month ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Closure of Trading Window
30 Jun - Trading window closed from 1 July 2026 until 48 hours after Q1 FY2027 results.
-
Announcement under Regulation 30 (LODR)-Credit Rating
29 Jun - CRISIL reaffirmed Medico Remedies' BBB-/Stable ratings on ₹42 crore bank facilities, enhanced from ₹19 crore.
-
Intimation Of Action Taken Or Order Passed By Regulatory,
Statutory, Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015
3 Jun - Medico Remedies paid Rs. 56,640 each to NSE and BSE for Regulation 6(1) non-compliance.
-
Audited Standalone Financial Results Of The Company For The Quarter Ended 31St March, 2026 And Audited Financial Statements For The Year Ended On 31St March, 2026 Along With The Auditor'S Report Thereon
21 May - Board approved FY26 audited standalone results; unmodified audit opinion, meeting held 21 May 2026.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
21 May - Medico Remedies confirms it is not a Large Corporate; outstanding borrowing was INR 0.35 crore on March 31, 2026.
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments